Genetic variance and plasma concentration of CD93 is associated with cardiovascular mortality: Results from a 6.7‑year follow‑up of a healthy community‑living elderly population

Abstract

Inflammation is one of the fundamental processes in numerous diseases. Cluster of differentiation (CD) 93, a glycoprotein, has been reported to be associated with a number of these diseases. There are reports indicating that a high plasma level of CD93 is associated with adverse events in ischaemic heart disease. Additionally, there are reports indicating different cardiovascular risks between different single nucleotide polymorphisms (SNPs) of CD93. Therefore, the present study aimed to determine whether the plasma concentration of CD93 and polymorphism of rs2749812 in CD93 were associated with clinical conditions and mortality in an elderly population. In 470 healthy elderly community-living individuals a novel clinical examination involving echocardiography and blood sampling was performed. The population was followed for 6.7 years. Plasma levels of CD93 and SNP analyses of rs2749812 of CD93 using PCR methodology were used. During the follow-up period, 106 (22.6%) all-cause and 61 (13.0%) cardiovascular deaths were registered. Those with the highest plasma concentration had markedly higher all-cause mortality. Evaluating the A/A, A/G and G/G genotypes, the G/G group exhibited significantly higher cardiovascular mortality (P=0.026), and an almost twofold increased risk in a multivariate Cox regression model compared with the A/G genotype. Evaluation of subgroups with respect to sex, diabetes and hypertension revealed markedly increased cardiovascular risk in the G/G genotype in all subgroups. All results persisted in the multiple models used. In the present study, the glycoprotein CD93 was demonstrated to have prognostic cardiovascular information, with increased risk for those with a high plasma concentration. Furthermore, the G/G genotype of rs2749812 of CD93 has a significantly higher cardiovascular risk, as demonstrated here, and could therefore be regarded as a possible cardiovascular risk biomarker that might in the future be used to offer optimised cardiovascular patient handling. However, this was a small study, and more research is required.

Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma

“…CD93 chimeric antigen receptor T cells eliminate acute myeloid leukemia and spare hematopoietic stem and progenitor cells but exert on-target, offtumor toxicity to endothelial cells (17). Notably, the expression of CD93 has an essential role in the pathogenesis of psoriasis, cardiovascular, and cerebrovascular diseases (18)(19)(20). These findings provide an idea for targeting CD93 therapy.…”

Diagnostic and Prognostic Role of CD93 in Cardiovascular Disease: A Systematic Review

“…Alehagen U. et al, 2020 [24] Population study of 457 individuals of both sexes aged between 70 and 85 years PCR quantification of CD93 SNP rs2749812 in plasma Cross-sectional differences plus all-cause and cardiovascular deaths in a mean follow-up of 6.7 years.…”

The C-Type Lectin Receptor CD93 Regulates Platelet Activation and Surface Expression of the Protease Activated Receptor 4

“…Increased levels of plasmatic sCD93 have been detected in various pathological conditions, including diabetes and myocardial infarction [14][15][16] . A recent study has demonstrated that increased plasmatic concentration of sCD93 is associated with cardiovascular mortality 17 .…”

“…[14][15][16] A recent study has demonstrated that increased plasmatic concentration of sCD93 is associated with cardiovascular mortality. 17 C-type lectin receptors are gaining growing interest as important regulators of platelet activation. 18 CLEC2 is a notable example and, since its discovery, this receptor has attracted attention for its contribution to platelet function in thrombosis, thromboinflammation, and cancer.…”

“…14 15 16 A recent study has demonstrated that increased plasmatic concentration of sCD93 is associated with cardiovascular mortality. 17…”